Rystiggo® (rozanolixizumab-noli) – New orphan drug approval
June 27, 2023 - UCB announced the FDA approval of Rystiggo (rozanolixizumab-noli), for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Top